How many courses of treatment are needed with gosatuzumab/Todavir?

Gosatuzumab/Trodelvy (Trodelvy) is an antibody-drug conjugate (ADC) targeting Trop-2. Its core mechanism is to use monoclonal antibodies to accurately recognize the highly expressed Trop-2 protein on the surface of tumor cells, and release the chemotherapy drug SN-38 through the linker to achieve cytotoxic killing in tumor cells. The drug is mainly used to treat advanced triple-negative breast cancer (TNBC) that has failed multiple lines of treatment in the past. In clinical practice, it has also gradually expanded to solid tumors such as HR+/HER2- breast cancer and metastatic urothelial cancer. Regarding the treatment course of gosatuzumab , a cycle of 21 days is generally considered, with one intravenous infusion on the 1st and 8th day. Most patients usually require multiple consecutive cycles of treatment, but there is no universal standard for the exact number of cycles.

The length of the treatment cycle depends on the patient's response to the drug, the controllability of side effects, and the progression of the tumor. In practical applications, as long as the tumor does not progress and the patient can tolerate the treatment, gosatuzumab can be used for several months or even longer. Some patients may observe shrinkage of lesions or improvement in symptoms after receiving 3-4 cycles, while some patients need to maintain more than 6-8 cycles to stabilize the disease. If disease progression or intolerable toxic reactions occur, such as severe neutropenia, diarrhea or fatigue, the doctor will evaluate whether to reduce the dose or terminate the medication.

In addition, doctors will periodically evaluate the treatment response and adjust treatment strategies in a timely manner based on factors such asCT images, tumor markers, and patient complaints. Therefore, "how many treatments are needed" is not an absolute number, but a dynamic decision-making process based on individual differences. For some patients with good responses, gosatuzumab may even extend progression-free survival and provide patients with more treatment opportunities. In general, the treatment course of gosatuzumab should be personalized under the guidance of professional oncologists, taking into account not only efficacy, but also safety and quality of life.

Reference materials:https://www.trodelvy.com/